JP2016528217A - 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療 - Google Patents

低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療 Download PDF

Info

Publication number
JP2016528217A
JP2016528217A JP2016529868A JP2016529868A JP2016528217A JP 2016528217 A JP2016528217 A JP 2016528217A JP 2016529868 A JP2016529868 A JP 2016529868A JP 2016529868 A JP2016529868 A JP 2016529868A JP 2016528217 A JP2016528217 A JP 2016528217A
Authority
JP
Japan
Prior art keywords
combination
taxane
paclitaxel
hypoxia activated
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016529868A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016528217A5 (https=
Inventor
ピー． ハート，チャールズ
ピー． ハート，チャールズ
ディー． サン，ジェシカ
ディー． サン，ジェシカ
エイ． エレンバース，ブライアン
エイ． エレンバース，ブライアン
グアルベルト，アントニオ
Original Assignee
スレッショルド ファーマシューティカルズ，インコーポレイテッド
スレッショルド ファーマシューティカルズ，インコーポレイテッド
メルク パテント ゲーエムベーハー
メルク パテント ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スレッショルド ファーマシューティカルズ，インコーポレイテッド, スレッショルド ファーマシューティカルズ，インコーポレイテッド, メルク パテント ゲーエムベーハー, メルク パテント ゲーエムベーハー filed Critical スレッショルド ファーマシューティカルズ，インコーポレイテッド
Publication of JP2016528217A publication Critical patent/JP2016528217A/ja
Publication of JP2016528217A5 publication Critical patent/JP2016528217A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016529868A 2013-07-26 2014-07-23 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療 Pending JP2016528217A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361859152P 2013-07-26 2013-07-26
US61/859,152 2013-07-26
US201361887873P 2013-10-07 2013-10-07
US61/887,873 2013-10-07
US201461994295P 2014-05-16 2014-05-16
US61/994,295 2014-05-16
PCT/US2014/047885 WO2015013448A1 (en) 2013-07-26 2014-07-23 Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane

Publications (2)

Publication Number Publication Date
JP2016528217A true JP2016528217A (ja) 2016-09-15
JP2016528217A5 JP2016528217A5 (https=) 2017-08-31

Family

ID=51299053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016529868A Pending JP2016528217A (ja) 2013-07-26 2014-07-23 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療

Country Status (5)

Country Link
US (1) US20160158253A1 (https=)
EP (1) EP3024490A1 (https=)
JP (1) JP2016528217A (https=)
CN (1) CN105792845A (https=)
WO (1) WO2015013448A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021519197A (ja) * 2018-03-23 2021-08-10 アデノサイト エルエルシー 強化された細胞病理学的細胞採取のための細胞および／または組織片の剥離を誘導する方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017192863A1 (en) 2016-05-04 2017-11-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
CN106279321A (zh) * 2016-08-09 2017-01-04 南京医科大学 吉西他滨ProTide乏氧活化前药及其应用
JP6975230B2 (ja) * 2016-10-05 2021-12-01 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. 患者モニタリングシステム及び方法
CN110680824A (zh) * 2018-07-05 2020-01-14 深圳艾欣达伟医药科技有限公司 埃夫索胺的抗癌医药用途
WO2023025312A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者
JP2024531479A (ja) 2021-08-27 2024-08-29 アセンタウィッツ ファーマシューティカルズ リミテッド 凍結乾燥製剤溶液および凍結乾燥製剤、ならびにそれらの方法および使用
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
US20250295677A1 (en) 2022-04-15 2025-09-25 Ascentawits Pharmaceuticals, Ltd. Method for treating cancer by using th-302 alone or in combination with parp inhibitor
CN119233822A (zh) 2022-05-23 2024-12-31 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
WO2024061346A1 (zh) 2022-09-22 2024-03-28 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
TW202434258A (zh) 2023-02-27 2024-09-01 大陸商深圳艾欣達偉醫藥科技有限公司 溶液、凍乾製劑、凍乾製劑單位包裝、注射液及注射液配製方法
AU2024317010A1 (en) 2023-07-28 2026-02-26 Ascentawits Pharmaceuticals, Ltd. Treatment of p53 gene mutation or defect negative cancer and tumor patients

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506448A (ja) * 2008-10-21 2012-03-15 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 低酸素活性化型プロドラッグを用いるがんの処置
JP2013527233A (ja) * 2010-06-04 2013-06-27 アブラクシス バイオサイエンス， エルエルシー 膵臓がんの処置方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPH07505887A (ja) * 1992-04-17 1995-06-29 アボツト・ラボラトリーズ タキソール誘導体
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
GB9909612D0 (en) 1999-04-26 1999-06-23 Cancer Res Campaign Tech N-protected amines and their use as prodrugs
NZ521851A (en) 2002-10-08 2005-02-25 Auckland Uniservices Ltd Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
US7629332B2 (en) 2003-10-31 2009-12-08 Auckland Uniservices Limited Nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents
CN102746336B (zh) 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
EP1931769A2 (en) 2005-10-03 2008-06-18 Genetix Pharmaceuticals Inc. Method for selectively depleting hypoxic cells
EP2114157B1 (en) 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer
CA2803113A1 (en) 2010-06-28 2012-01-12 Threshold Pharmaceuticals, Inc. Treatment of blood cancer
WO2012009288A2 (en) 2010-07-12 2012-01-19 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
JP2014509658A (ja) * 2011-04-01 2014-04-21 スレッショルド ファーマシューティカルズ、インク． ガン処置方法
KR20140045931A (ko) 2011-04-15 2014-04-17 쓰레솔드 파마슈티컬스, 인코포레이티드 경구 투여를 위한 단위투여량 형태
WO2013096687A1 (en) 2011-12-22 2013-06-27 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer
EP2793899A4 (en) 2011-12-22 2015-06-17 Threshold Pharmaceuticals Inc HYPOXIA-ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR CANCER TREATMENT
US20160045522A1 (en) 2012-02-21 2016-02-18 Threshold Pharmaceuticals, Inc. Treatment of Cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506448A (ja) * 2008-10-21 2012-03-15 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 低酸素活性化型プロドラッグを用いるがんの処置
JP2013527233A (ja) * 2010-06-04 2013-06-27 アブラクシス バイオサイエンス， エルエルシー 膵臓がんの処置方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANNALS OF ONCOLOGY MEETING ABSTRACT, JPN5016008497, October 2010 (2010-10-01), ISSN: 0003907011 *
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 71, no. 4, JPN6018012668, 13 March 2013 (2013-03-13), pages 1065 - 1072, ISSN: 0003907014 *
MOLECULAR AND CELLULAR PROTEOMICS, vol. 10, JPN6018012671, 2011, pages 1 - 20, ISSN: 0003907013 *
QIAN LIU: "TH-302, A HYPOXIA-ACTIVATED PRODRUG WITH BROAD IN VIVO PRECLINICAL COMBINATION 以下備考", CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. VOL:69, NR:6,, JPN5016008496, 2 March 2012 (2012-03-02), DE, pages 1487 - 1498, ISSN: 0003907015 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 10, JPN6018012669, 2011, pages 7779 - 7787, ISSN: 0003907012 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021519197A (ja) * 2018-03-23 2021-08-10 アデノサイト エルエルシー 強化された細胞病理学的細胞採取のための細胞および／または組織片の剥離を誘導する方法
JP7500536B2 (ja) 2018-03-23 2024-06-17 アデノサイト リミテッド 強化された細胞病理学的細胞採取のための細胞および／または組織片の剥離を誘導する方法

Also Published As

Publication number Publication date
CN105792845A (zh) 2016-07-20
US20160158253A1 (en) 2016-06-09
EP3024490A1 (en) 2016-06-01
WO2015013448A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
JP2016528217A (ja) 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療
Schmid et al. Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor–positive metastatic breast cancer: the MANTA phase 2 randomized clinical trial
US8003105B2 (en) Method of treating cancer by co-administration of anticancer agents
RU2576609C2 (ru) Способы лечение рака поджелудочной железы
EP2786754B1 (en) Combination therapy with a mitotic inhibitor
AU2012321106B2 (en) Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent
JP4778679B2 (ja) 併用薬剤を送達するための組成物
CA2960989A1 (en) Human dosing of phosphatase inhibitor
BR112018002941B1 (pt) Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas
JP7113619B2 (ja) リポソーマルイリノテカンによる乳がんの治療
Kelley et al. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206
Federico et al. Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours
Cohen et al. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer
TWI469776B (zh) 有助於癌症之治療的方法，組成物以及製品
Gebbia et al. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the GOIM (Gruppo Oncologico Italia Meridionale)
Hainsworth et al. Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC)
Di Lauro et al. Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer
Utkan et al. Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma
Garces et al. Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer
Massa et al. Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens
Hirose et al. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer
US20250049807A1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
Huisman et al. A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients
US20220071982A1 (en) Methods and uses for treating cancer
Rosenthal et al. Phase I Study of Paclitaxel Given by Seven-Week Continuous Infusion Concurrent with Radiation Therapy for Locally Advanced Non–Small Cell Lung Cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181029